| Literature DB >> 29117668 |
Ja Yun Choi1, Yun Won Jo1, Sang Soo Lee1,2, Wan Soo Kim1,2, Hye Won Oh1, Cha Young Kim1, Eun Young Yun1, Jin Joo Kim1,2, Jae Min Lee1,2, Hong Jun Kim1, Hyun Jin Kim1,2,3, Tae Hyo Kim1,3, Woon Tae Jung1,3, Ok Jae Lee1,3, Rock Bum Kim4.
Abstract
Background/Aims: The aim of this study was to investigate the mortality, bleeding control rate, and their associated predictors in patients treated with Sengstaken-Blakemore (SB) tube for uncontrolled variceal hemorrhage associated with hemodynamic instability or failure of endoscopic treatment.Entities:
Keywords: Hemostasis; Mortality; Sengstaken-Blakemore tube; Variceal hemorrhage
Mesh:
Year: 2017 PMID: 29117668 PMCID: PMC6030415 DOI: 10.3904/kjim.2016.339
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Figure 1.Outcomes of patients treated with Sengstaken-Blakemore (SB) tube for uncontrolled variceal hemorrhage. Emergency transjugular intrahepatic portosystemic shunt (TIPS) was not available in our center.
Baseline characteristics of patients who were treated with Sengstaken-Blakemore tube for acute uncontrolled variceal hemorrhage
| Characteristic | Value (n = 66) |
|---|---|
| Male sex | 62 (93.9) |
| Age, yr | 53.0 (46.8–59.5) |
| Etiology of cirrhosis, alcohol/viral + alcohol/viral | 49/8/9 (74.2/12.1/13.6) |
| Hepatocellular carcinoma | 14 (21.2) |
| Previous variceal hemorrhage | 47 (71.2) |
| Ascites, absent/mild to moderate/severe | 18/26/22 (27.3/39.4/33.3) |
| Overt encephalopathy | 28 (42.4) |
| Child-Pugh score | 11.0 (8.0–12.3) |
| MELD score | 18.5 (13.0–27.3) |
| Hemoglobin, g/dL | 7.5 (6.2–9.2) |
| Platelet, × 1,000/μL | 90.0 (66.5–120.8) |
| Bilirubin, g/dL | 2.5 (1.5–4.5) |
| INR | 1.83 (1.49–2.75) |
| Albumin, g/dL | 2.6 (2.0–2.9) |
| AST, IU/L | 79.0 (50.5–126.8) |
| ALT, IU/L | 27.5 (19.8–56.3) |
| Na, mmol/L | 136.8 (133.5–139.2) |
| WBC, 10 × 109/L | 8.7 (6.2–13.0) |
Values are presented as number (%) or median (interquartile range).
MELD, model for end-stage liver disease; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransaminase; WBC, white blood cell.
Management of variceal hemorrhage at the time of initial hemorrhage in patients with SB tube (n = 66)
| Characteristic | No. (%) |
|---|---|
| Source of hemorrhage, esophageal/gastric varix | 55/11 (83.3/16.7) |
| Endoscopy before SB tube insertion | 33 (50.0) |
| Endotracheal intubated state before SB tube insertion | 18 (27.3) |
| Terlipressin | 66 (100) |
| Gastric balloon/gastric and esophageal balloons | 16/50 (24.2/75.8) |
| Reasons of SB tube insertion | |
| Severe encephalopathy | 6 (9.1) |
| Failure of endoscopic hemostasis | 26 (39.4) |
| Hemodynamic instability | 34 (51.5) |
SB, Sengstaken-Blakemore.
Outcomes of patients who were treated with SB tube for acute uncontrolled variceal hemorrhage
| Outcome | No. (%) |
|---|---|
| Initial hemostasis with SB tube (n = 66) | 50 (75.8) |
| Rebleeding after successful hemostasis with SB tube (n = 50) | 11 (22.0) |
| Esophageal perforation (n = 66) | 4 (6.1) |
| Death (n = 66) | 28 (42.4) |
| Causes of death (n = 28) | |
| After failed successful initial hemostasis with SB tube (n = 16) | |
| Failure of successful hemostasis | 12 (42.9) |
| Esophageal perforation | 4 (14.3) |
| After successful initial hemostasis with SB tube (n = 12) | |
| Among patients with rebleeding (n = 6) | |
| Failed successful hemostasis | 5 (17.9) |
| Multi-organ failure | 1 (3.6) |
| Among patients without rebleeding (n = 6) | |
| Multi-organ failure | 6 (21.4) |
SB, Sengstaken-Blakemore.
Figure 2.Cumulative survival rate according to success of initial hemostasis with Sengstaken-Blakemore tube (A) and endotracheal intubation (B).
Independent predictors for initial hemostasis among patients who were treated with SB tube for acute variceal hemorrhage (n = 66)
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Age < 53 yr | 1.67 (0.53–5.29) | 0.386 | - | - |
| Non-intubated state before SB tube | 8.75 (2.48–30.95) | 0.001 | 8.50 (1.80–40.25) | 0.007 |
| Absence of overt HEP | 6.38 (1.78–22.89) | 0.005 | - | - |
| Hemoglobin > 8 g/dL | 1.310 (0.41–4.16) | 0.648 | - | - |
| WBC < 10 × 109/L | 5.13 (1.52–17.35) | 0.008 | 3.89 (0.65–23.20) | 0.136 |
| INR < 1.83 | 4.14 (1.17–14.65) | 0.027 | - | - |
| Na > 135 mmol/L | 4.29 (1.31–14.03) | 0.016 | 3.74 (0.80–17.50) | 0.094 |
| MELD < 19 | 5.82 (1.63–20.82) | 0.007 | 0.204 (0.02–2.45) | 0.204 |
| Child-Pugh score < 11 | 10.50 (2.15–51.28) | 0.004 | 15.65 (1.35–181.48) | 0.022 |
SB, Sengstaken-Blakemore; OR, odds ratio; CI, confidence interval; HEP, hepatic encephalopathy; WBC, white blood cell; INR, international normalized ratio; MELD, model for end-stage liver disease.
Independent predictors for 30 days mortality among patients treated with SB tube for acute variceal hemorrhage (n = 66)
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Age < 53 yr | 1.08 (0.51–2.27) | 0.838 | - | - |
| Ischemic hepatitis[ | 2.20 (1.01–4.79) | 0.047 | 1.90 (0.83–4.34) | 0.129 |
| Endotracheal intubation before SB tube | 5.33 (2.45–11.60) | < 0.001 | 2.81 (1.12–6.64) | 0.018 |
| Failure of initial hemostasis with SB tube | 14.67 (5.74–37.49) | < 0.001 | 6.24 (2.26–17.24) | < 0.001 |
| Overt HEP | 4.10 (1.84–9.19) | 0.001 | - | - |
| Moderate to severe ascites | 3.27 (1.53–6.95) | 0.002 | - | - |
| Hemoglobin < 8 g/dL | 1.43 (0.66–3.11) | 0.362 | - | - |
| WBC < 10 × 109/L | 3.49 (1.60–7.62) | 0.002 | - | - |
| INR < 1.83 | 4.67 (1.88–11.59) | 0.001 | - | - |
| Albumin > 2.5 g/dL | 2.66 (1.12–5.90) | 0.016 | - | - |
| Na < 135 mmol/L | 2.35 (1.11–4.95) | 0.025 | 0.74 (0.31–1.74) | 0.129 |
| MELD ≥ 18 | 6.54 (2.63–16.31) | < 0.001 | 1.21 (0.27–5.56) | 0.803 |
| Child-Pugh score ≥ 11 | 8.01 (2.76–23.24) | < 0.001 | 4.13 (0.87–19.55) | 0.074 |
SB, Sengstaken-Blakemore; HR, hazard ratio; CI, confidence interval; HEP, hepatic encephalopathy; WBC, white blood cell; INR, international normalized ratio; MELD, model for end-stage liver disease.
Ischemic hepatitis: defined as aspartate aminotransferase > 500 IU/L or alanine aminotransaminase > 500 IU/L within 24 hours.